Pituitary tumors in 2010: A new therapeutic era for pituitary tumors

Nature Reviews Endocrinology

Volumn 7, Issue 2, 2011, Pages 71-73

  Gueorguiev, Maria ^a   Grossman, Ashley B ^a  

^a QUEEN MARY UNIVERSITY OF LONDON   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

ALKYLATING AGENT; ANGIOPEPTIN; BIM 23A760; CABERGOLINE; DACARBAZINE; KETOCONAZOLE; OCTREOTIDE; PASIREOTIDE; PEGVISOMANT; TEMOZOLOMIDE; UNCLASSIFIED DRUG;

ACROMEGALY; ADD ON THERAPY; ARTICLE; CANCER RADIOTHERAPY; CANCER SURGERY; CANCER THERAPY; CUSHING DISEASE; CUSHING SYNDROME; DRUG EFFICACY; DRUG INHIBITION; DRUG TARGETING; DRUG WITHDRAWAL; HUMAN; HYPERCHOLESTEROLEMIA; HYPOCORTISOLISM; HYPOPHYSIS ADENOMA; HYPOPHYSIS TUMOR; MULTIPLE CYCLE TREATMENT; PHASE 3 CLINICAL TRIAL (TOPIC); PRIORITY JOURNAL; TREATMENT RESPONSE;

ACROMEGALY; CLINICAL TRIALS AS TOPIC; DOPAMINE; HUMANS; MODELS, BIOLOGICAL; PITUITARY ACTH HYPERSECRETION; PITUITARY NEOPLASMS; SOMATOSTATIN;

EID: 79251638304     PISSN: 17595029     EISSN: 17595037     Source Type: Journal    
DOI: 10.1038/nrendo.2010.233     Document Type: Article

References (10)

1. Boscaro, M. et al. Treatment of pituitarydependent Cushings disease with the multireceptor ligand somatostatin analog pasireotide (SOM230): a multicenter, phase ii trial. J. Clin. Endocrinol. Metab. 94, 115-122 (2009).
2. Colao, a. et al. Pasireotide (SOM230) provides clinical benefit in patients with Cushings disease: results from a large, 12-month, randomized-dose, double-blind, phase iii study [abstract]. 14th european neuroendocrine association Congress (abstract OC-1.7) (2010).
3. Feelders, r. a. et al. Pasireotide alone or with cabergoline and ketoconazole in Cushings disease. N. Engl. J. Med. 362, 1846-1848 (2010).
4. Petersenn, S. et al. Pasireotide acromegaly Study Group. Pasireotide (SOM230) demonstrates efficacy and safety in patients with acromegaly: a randomized, multicenter, phase ii trial. J. Clin. Endocrinol. Metab. 95, 2781-2789 (2010).
5. Peverelli, e. et al. The dopamine-somatostatin chimeric compound BiM-23a760 exerts antiproliferative and cytotoxic effects in human non-functioning pituitary tumors by activating erK1/2 and p38 pathways. Cancer Lett. 288, 170-176 (2010).
6. Lesage, C. et al. a phase ii exploratory study of BiM23a760 in acromegalic patients: Preliminary results of safety and efficacy after a single-dose administration [abstract P3-673]. The endocrine Societys annual meeting (2009).
7. raverot, G. et al. Temozolomide treatment in aggressive pituitary tumors and pituitary carcinomas: a French multicenter experience. J. Clin. Endocrinol. Metab. 95, 4592-4599 (2010).
8. McCormack, a. i. et al. Low O6- methylguanine- Dna methyltransferase (MGMT) expression and response to temozolomide in aggressive pituitary tumours. Clin. Endocrinol. (Oxf.) 71, 226-233 (2009).
9. Kovacs, K. et al. MGMT immunoexpression predicts responsiveness of pituitary tumors to temozolomide therapy. Acta Neuropathol. 115, 261-262 (2008).
10. Bush, Z. M. et al. Temozolomide treatment for aggressive pituitary tumors: correlation of clinical outcome with O6-methylguanine methyltransferase (MGMT) promoter methylation and expression. J. Clin. Endocrinol. Metab. 95, e280-e290 (2010).